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960calcium scoring was performed for the entire patient
population.
There were no statistically signiﬁcant differences in
age, sex, blood pressure, Framingham Risk Score
(FRS), lipid proﬁle, or statin use between the RA Group
and Matched Controls. Arterial target-to-background
ratio (TBR) was signiﬁcantly higher in RA versus
Matched Controls (2.150.29 vs. 1.840.32; p¼0.001)
(Figures 1A and 1C). This difference remained signiﬁ-
cant after adjusting for age, sex, hypertension, dia-
betes, smoking, dyslipidemia, and body mass index
(b ¼ 0.273; p ¼ 0.001) and after adjusting for statin use,
low-density lipoprotein (LDL) and high-density lipo-
protein (b ¼ 0.297; p ¼ 0.002).
The difference in arterial TBR remained consistent
across subgroup analyses. In patients with FRS <10,
TBR was higher in subjects with RA (2.06  0.25 vs.
1.80  0.17; p ¼ 0.001). Likewise, arterial TBR
remained signiﬁcantly higher in the RA Group in
patients: 1) without coronary calcium (p ¼ 0.002); 2)
with LDL <130 mg/dl (p ¼ 0.01); or 3) who were statin
naive (p < 0.001). Because a subset of the patients
were cancer survivors undergoing surveillance scan-
ning, we evaluated the between-group differences
after adjusting for prior cancer chemotherapy and
radiotherapy, and observed a persistent increase in
arterial TBR among those with RA (b ¼ 0.34, p <
0.001).
Moreover, we observed a signiﬁcant correlation
between synovial and arterial FDG uptake (SUV)
in patients with RA (R ¼ 0.42, p ¼ 0.015), but
not in controls (R ¼ 0.28, p ¼ 0.11). This relation-
ship remained signiﬁcant after correcting for
background venous activity (TBR) (R ¼ 0.55, p¼ 0.001)
(Figure 1B). By contrast, there was no signiﬁcant cor-
relation between arterial versus SAT FDG uptake (R ¼
0.17; p ¼ 0.14). We did not observe a correlation be-
tween C-reactive protein levels and arterial (p ¼ 0.67)
or synovial FDG uptake (p ¼ 0.42).
In this study, we demonstrated that patients with
RA have signiﬁcantly higher arterial FDG uptake
compared with matched controls that remained sig-
niﬁcant after adjusting for atherosclerosis risk fac-
tors and statin therapy. Furthermore, we observed a
signiﬁcant correlation between synovial activity and
arterial FDG uptake. Collectively, these ﬁndings
suggest that patients with RA have elevated levels of
arterial inﬂammation beyond that predicted by
traditional risk factors, and that arterial inﬂamma-
tion may be related to the severity of RA disease
activity (measured as synovial activity). Because
arterial FDG uptake has been associated with the risk
of subsequent CVD (at least in patients without RA)
(3), these ﬁndings add to the body of evidencelinking RA disease activity with potentiated risk
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403–10.Delayed Transcatheter Heart Valve
Migration and FailureDelayed downward migration of the SAPIEN trans-
catheter heart valve (THV) (Edwards Lifesciences
Corporation, Irvine, California) is a rare com-
plication after transcatheter aortic valve replace-
ment (TAVR) (1–3). THV migration into the left
ventricle has been described 2 to 43 days after
deployment and is associated with cardiogenic shock
(1,2) or disruption of mitral valve function (3). We
describe 2 additional presentations associated with
delayed downward THV migration: native valve
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961restenosis and rapid THV degeneration with severe
aortic regurgitation. The choice of the size of the THV
in both cases was on the basis of 2-dimensional
transesophageal echocardiography (TEE)-determined
aortic annulus diameter consistent with practice
during early experience with TAVR. The aortic
annulus area according to computed tomography (CT)
or 3-dimensional TEE was not determined. The 2
cases described occurred after the learning curve (4),
when w100 TAVR procedures had been performed.
A 79-year-old female patient with symptomatic
low gradient severe aortic stenosis, aortic valve area
of 0.78 cm2, mean gradient of 21 mm Hg
(increased to 41 mm Hg with dobutamine), and
left ventricular ejection fraction of 40% underwent
transapical TAVR with a 23-mm SAPIEN THV
(Edwards Lifesciences Corporation). The patient’s
Society of Thoracic Surgeons risk score was 15.5%.
The TEE long-axis view showed a normal appearance
of the THV (Figure 1A, arrows) immediately post-
deployment, and there was mild periprosthetic
regurgitation and a normal THV gradient of 5 mm Hg.
Pre-discharge transthoracic echocardiogram 7 days
post-TAVR showed a THV systolic mean gradient of
19 mm Hg and mild regurgitation. At 3 months’
follow-up, the patient complained of recurrent dys-
pnea, and the THV was noted to have migratedFIGURE 1 Delayed THV Migration
(A) Normal transcatheter heart valve (THV) and leaﬂets (arrows) long-ax
axis view. (C) THV immediately post-deployment short-axis view showing
5, and 9 o’clock (arrows). (D) Native aortic valve leaﬂets above the THV s
12, 4, and 8 o’clock (arrows). (E) Native aortic valve leaﬂet overhang (a
leaﬂets (arrows) above the THV long-axis view. (G) Color ﬂow imaging
and THV as a result of native valve–THV interaction. (H) The second THdownward, with native leaﬂets visualized above the
THV on TEE imaging (Figure 1B, arrows). The TEE
short-axis view displayed the different position of
THV commissures (Figure 1C, arrows) and native
leaﬂet commissures (Figure 1D, arrows), and the mean
gradient was increased to 23 mm Hg. The patient was
subsequently diagnosed with supraprosthetic native
valve restenosis, which in retrospect may have
occurred earlier (pre-discharge) and was not recog-
nized. She was managed medically.
An 82-year-old male patient with severe aortic
stenosis, aortic valve area of 0.93 cm2, mean gradient
of 54 mm Hg, left ventricular ejection fraction
of 70%, and a Society of Thoracic Surgeons risk
score of 9.5% underwent transfemoral TAVR with a
26-mm SAPIEN valve on the basis of a 2-dimensional
TEE aortic annulus diameter of 24 mm. There
was native leaﬂet overhang immediately post-THV
placement (Figure 1E, arrow) and associated moder-
ate periprosthetic regurgitation. The mean gradient
was 12 mm Hg. Periprosthetic regurgitation was mild
7 days post-TAVR; the mean gradient was 20 mm Hg.
At 1 year, the patient had recurrent dyspnea and heart
failure. TEE demonstrated that the THV gradient was
39 mm Hg and offered evidence of supraprosthetic
native aortic valve restenosis on long-axis view
(Figure 1F, arrows) and short-axis views and associatedis view. (B) Native aortic valve leaﬂets (arrows) above the THV long-
mild periprosthetic regurgitation (color); note THV commissures at 1,
hort-axis view; note different position of native leaﬂet commissures at
rrow) long-axis view post-THV deployment. (F) Native aortic valve
long-axis view showing severe regurgitation through the native valve
V pre-deployment was slightly superior (arrow) to the ﬁrst THV.
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962severe transprosthetic regurgitation (Figure 1G). The
THV leaﬂets appeared torn. The patient subsequently
underwent successful repeat transfemoral valve-in-
valve TAVR with a second 26-mm SAPIEN THV placed
slightly superior to the ﬁrst THV (Figure 1H, arrow
[before deployment]). There was moderate peri-
prosthetic residual regurgitation despite post-THV
deployment balloon dilatation, but native leaﬂet
overhang was eliminated. At 1-year follow-up after the
valve-in-valve TAVR, the THV mean gradient was 14
mm Hg, and the degree of periprosthetic regurgitation
was mild. In retrospect, the aortic valve annulus
diameter according to computed tomography scan
measured 28 mm, suggesting that the 26-mm THV was
undersized.
Mechanisms responsible for downward THV
migration can include native leaﬂet overhang post-
deployment, exerting downward force on the THV
(1,2) or limited anchoring of the THV from low
deployment in a relatively large and nonseverely
calciﬁed annulus (1) or from deployment of a
THV that is too small for the native aortic valve
annulus. Although rare, delayed THV migration
should be suspected when there is a worsening of
the patient’s clinical status or unfavorable THV he-
modynamic proﬁle (increasing mean gradient or
worsening regurgitation) on follow-up echocardio-
graphic examination.Vuyisile T. Nkomo, MD, MPH*
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Coll Cardiol Intv 2012;5:72–9.LA Emptying Fraction Improves Diagnosis
of Paroxysmal AF After Cryptogenic Ischemic
Stroke: Results From the SURPRISE StudyIn 25% of patients with ischemic stroke, no etiologic
factor is identiﬁed: so-called cryptogenic strokes (CS)
(1). Asymptomatic paroxysmal atrial ﬁbrillation (PAF)
is often suspected to be the cause of stroke in these
patients.
Echocardiographic estimates of left atrial (LA)
function, such as the left atrial emptying fraction
(LAEF), can easily be determined by echocardiogra-
phy and could potentially be a surrogate marker for
already present PAF (2).
The aim of this study was to establish if echocar-
diographic investigation of the LA function would
identify patients with subsequent documentation of
PAF following a CS.
A total of 58 patients with CS were included in the
SURPRISE (Stroke Prior to Diagnosis of Atrial Fibrilla-
tion Using Longterm Observation with Implantable
Cardiac Monitoring Apparatus Reveal) study (clinical
trial number NCT01498146) and underwent conven-
tional 2-dimensional echocardiography a median of
42 days (interquartile range [IQR]: 14 to 134 days) after
the stroke as part of the clinical work-up to identify if
the heart was the source of the ischemic stroke. All
patients had an insertable cardiac monitor implanted
within a time interval after their stroke as per the
current practice recommendations (median 69 days,
IQR: 42 to 127 days). Left atrial volumes (LAV)
were estimated by the biplane area-length method in
the apical 4- and 2-chamber views. The maximal LAV
was measured during left ventricular (LV) end-systole
and minimal LAV during LV end-diastole. The LAEF
was calculated as: (maximal LAV  minimal LAV)/
(maximal LAV). During the course of follow-up (me-
dian 20months, IQR: 11 to 29months) 13 (22%) patients
were diagnosed with PAF. Follow-up was 100%. Atrial
ﬁbrillation was diagnosed a median of 59 days (IQR: 8
to 109 days) after implantation of the insertable car-
diac monitor. No patient experienced any symptoms
in conjunction with the diagnosis of atrial ﬁbrillation.
Patients subsequently diagnosed with PAF were
signiﬁcantly older (65  8 years vs. 51  12 years, p <
0.001) and had signiﬁcantly higher mean CHADS2
(Congestive heart failure, Hypertension, Age $75
years, Diabetes mellitus, Stroke) score (2.9  1.1 vs.
2.4  0.6, p ¼ 0.022) than patients without PAF. Other
than age and CHADS2 score, no baseline characteristic
(sex, hypertension, diabetes, cholesterol, blood
sugar, or body mass index) was associated with PAF.
No patient was diagnosed with an evident
cardioembolic source as a consequence of the
